Eric Shaff, President and CEO of Seres Therapeutics, reflects on the founding premise of Seres— that certain populations of microbes could benefit human health and intervene in disease — and shares what’s ahead for the company with what could be the first approved oral microbiome therapeutic. More from Flagship @ JPM2023 here.
Related Companies
- Seres Therapeutics Founded: 2011
